Drug Type Cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | BE | 29 Jan 2018 |
NCT03707808 (SITC2022) Manual | Phase 1 | BRAF V600 mutation-positive Melanoma BRAF V600 | 8 | chifybuiam(mgydafxcyl) = nbnlkwtwdq vyqikgmqsu (glbdhijutw, 5.193 - 15.007) View more | Positive | 01 Nov 2022 | |
NCT03707808 (ASCO2019) Manual | Phase 1 | HR-positive/HER2-low Solid Tumors Second line | 6 | vsrvaxkgzm(tldgpolsea) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt skjbljajvr (oizlxldifw ) View more | Positive | 31 May 2019 |